BEIJING, June 29 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced the recent publication of a large sample study on the Company's SPR analyzer and related HPV DNA chip (the "SPR System") for the detection of 16 high risk and 8 low risk genotypes of human papillomavirus ("HPV"). The study tested specimens of 560 patients with atypical squamous cells of undetermined significance ("ASCUS") or above using the SPR System and compared the results with sequence analysis. The study concluded that the SPR System is highly sensitive and specific in HPV genotyping (99% concordance between the SPR System and sequence analysis) and can become an effective approach for HPV genotyping in a clinical setting.
The study is entitled, "A Surface Plasmon Resonance-based System to Genotype Human Papillomavirus", and can be found in the online edition of the medical journal Cancer Genetics and Cytogenetics, Volume 200, Issue 2, at http://cancergeneticsjournal.org  .
The Company also announced the creation of a new column "Medical Publications" in its investor relations section at http://ir.chinameditech.com  which currentl